Several members of our Symbio staff had the pleasure of attending this year’s AAD conference in New Orleans. It was an amazing opportunity to connect with our clients in person and meet the companies and individuals responsible for driving innovation in dermatology.
We would like to express our gratitude to all of those who came to visit us, both at our booth and at our festive night at the House of Blues. We can’t wait to return to AAD next year in San Diego, and we are anxious to see all of our colleagues again!
The newest white paper in Symbio’s white paper series was recently released entitled, “Atopic Dermatitis: Considerations for Clinical Trials.” This paper explores the clinical research challenges involved in AD trials including lack of standardized rating scales, the need to enroll children and young people, and the impact of time of year and geographic region.
Atopic dermatitis (AD), often called eczema, is a common and often debilitating skin condition whose root cause remains unknown but is likely to be related to allergies and immune dysregulation. No curative treatment exists for this condition and management usually consists of topical corticosteroids. In more severe cases, topical calcineurin inhibitors, biologics or immunosuppressants may be necessary. Unless remission occurs, AD is a chronic disease and needs to be suppressed through medication and vigorous hygiene practices.
AD’s prevalence, lack of cure, and impact on life quality have driven continuous research and investment into novel therapies. Unless an extremely tolerable and efficacious treatment becomes available, this trend is likely to continue.
Symbio has released their latest white paper “The Clinical State of Psoriasis” which aims to explain why biologics have become so popular and why their introduction has been so disruptive to classic topical drug studies.
Psoriasis is a common and often debilitating skin disease that affects millions of Americans each year. In the last few decades a variety of different pharmaceutical interventions have been brought to market with the intention of alleviating the suffering this ailment inflicts. These efforts have coalesced into two main classes of drugs: Topical medications and systemic treatments. These systemic, biologic treatments generally come from a newer class of drugs known as monoclonal antibodies, or MABs.
As the psoriasis market expands to include new systemic agents, clinical trials and their enrollment become increasingly complex. Due to the rise of treatment options such as biologics, topical psoriasis drugs have seen slow enrollment over the last decade
Symbio and Dow Development Laboratories exhibited at the 2022 AAD Annual Meeting from March 25 to March 29 at the Boston Convention & Exhibition Center in Boston, MA. The event was a huge success for all. It was wonderful to see so many familiar faces and to make new connections.
View videos of AAD Annual Meeting at the Symbio Booth and our 20th Anniversary Dinner Celebration at SPIN.
Symbio and Dow Development Laboratories exhibited at the 28th EADV Congress, “The Modern Face of Dermatology” from October 9 to October 13, 2019 at IFEMA Congress Centre in Madrid, Spain.
The show was a great success as we were able to connect with our clients, friends and colleagues.
Founded in 1987, EADV is a non-profit association whose mission is to advance excellence in clinical care, research, education and training in the field of dermatology and venereology and to act as the advocate and educator of patients particularly those with cutaneous or venereal diseases.
Symbio and Dow Development Laboratories were glad to exhibit at the 2019 AAD Annual Meeting from March 1 to March 5, 2019 at the Walter E. Washington Convention Center in Washington, DC at Booth #s 3556 and 3558!
We had enlightening discussions with many amazing people, and the meeting was a huge success!
Symbio and Dow Development Laboratories were at the 5th Annual Dermatology Innovation Forum on February 28, 2019 from 8am to 5pm at the Washington Hilton in Washington, DC.
As a supporting Sponsor we supported the Forum’s goals of educating participants about inspiring innovations that can provide a basis for the generation of important dermatology products and services. By including physicians, researchers, inventors, investors, strategic corporate partners, service providers, government regulators, patient advocates, and other stakeholders, the Forum also provided a unique networking venue for its attendees to communicate with, learn from, and collaborate with each other.